Targeted management of hyperglycemia and hypertension using insulin, metformin, labetalol, or nifedipine achieved a reduction in adverse outcome rates from 87.8% in untreated patients to 16.98% in those receiving therapy, highlighting the importance of a dual-targeted approach. The gene discussed is INS; the disease is Hyperglycemia.